Somnomed Limited · ASX:SOM
Somnomed — Wilsons Drug and Device Conference 2023
9 slides from Somnomed's conference presentation, Oct 26, 2023
Slide 1: Wilsons Drug and Device Conference
For personal use only Wilsons Drug and Device Conference October 2023 Mark Harding Senior Vice President Global Marketing and R&D. 1
Slide 2: Investment Thesis to date...
Investment Thesis to date... ▪ Operating in 28 countries (17 with direct sales ▪ OSA is highly prevalent and undiagnosed teams) . medical condition, associated with cardiovascular ▪ 8 regional hubs delivering support to local dental and metabolic diseases and medical customers. ▪ SOM’s TAM continues
Slide 3: Growth Track Record
Growth Track Record Total Revenue ($m)1 Rest Assure will drive a step change in revenue growth Covid impacted 73 CAGR: For personal use only 16% 63 59 57 52 48 44 34 30 19 FY13A FY14A FY15A FY16A FY17A* FY18A* FY19A* FY20A FY21A FY22A Ongoing focus on increased Expansion of both Dental and OAT aware
Slide 4: Rest Assure - Addressing barriers to OAT prescription
Rest Assure - Addressing barriers to OAT prescription For personal use only 4
Slide 5: How does Rest Assure address OAT barriers?
How does Rest Assure address OAT barriers? A SOM market research: Key barriers to prescribing OAT ▪ Currently physicians don’t know if a patient has an oral device, if 242 Sleep Physicians - conducted in Oct 2019 they’re wearing it and if it’s working. They know this with CPAP Lack of night-time mon
Slide 6: Intended market rollout strategy
Intended market rollout strategy Steps to market Rest Assure Marketing strategy ▪ Rest Assure will be marketed as a premium Rest Assure submission to the US FDA OAT product, where local reimbursement allows For personal use only Launch ▪ Rest Assure will launch first in countries where it is classif
Slide 7: Rest Assure enables DTP marketing
Rest Assure enables DTP marketing. ▪ Direct to Patient (DTP) campaigns in For personal use only Facebook in US and ANZ conducted to test DTP systems (using Salesforce/ Marketo) Pre-Rest Assure DTP ▪ Campaigns direct patients to “Find A Provider” pilots. on SOM website, linking patients with dentists
Slide 8: SomnoMed's vision in one page
SomnoMed’s vision in 1 page. OSA Market Overview SomnoMed Overview Market Opportunity Treatment landscape Market Growth opportunity 3 primary treatment options currently available Almost 1 billion people suffer from OSA Raise awareness to treat Obstructive Sleep Apnea (OSA) globally. The most popula
Slide 9: Disclaimer
Disclaimer This Presentation: (i) contains summary information about SomnoMed and its subsidiaries (the Group) and their activities current as at the date of this Presentation; (ii) is for information purposes only and is not, and does not comprise all of the information which would be required to b